Agree mega.
Of memory, I believe the medium durability data on the breastcancer study now well over the 30 month stage.
Viewing this, as well as the Ovarian study ( both results above the baseline) as now more on durability data, may be, not necessarily though, as to why both studies are in-active.
That is, be it feedback or not by peers, yes the target is has met efficacy but what is it’s longevity?
Just an inference, no factual knowledge that that is the case.
Ann: PTX Receives Two US Patents Covering PTX-200, page-9
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
